Valuation: Genmab A/S

Market Cap 223B 33.05B 29.86B 27.58B 24.97B 47.08B 3,108B 48.52B 331B 132B 1,663B 124B 121B 5,280B P/E 2026 *
41.2x
P/E 2027 * 32x
Enterprise Value 242B 35.8B 32.34B 29.87B 27.04B 50.99B 3,366B 52.54B 358B 142B 1,801B 134B 131B 5,718B EV / Sales 2026 *
8.09x
EV / Sales 2027 * 6.46x
Free-Float
94.3%
Yield 2026 *
-
Yield 2027 * -
1 day-0.87%
1 week-1.34%
Current month-9.76%
1 month+44.38%
3 months+77.12%
6 months+112.78%
Current year+74.15%
1 week 3,435
Extreme 3435
3,728
1 month 2,404
Extreme 2404
3,947
Current year 1,512
Extreme 1512
3,947
1 year 1,512
Extreme 1512
3,947
3 years 1,157
Extreme 1157
3,947
5 years 1,157
Extreme 1157
3,947
10 years 786.2
Extreme 786.2
3,947
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
12/1/25 A Exercice

Director

189 0.0003%
12/1/25 A Exercice

Director

189 0.0003%
12/1/25 A Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-0.87%-1.34%+83.95%+63.96% 33.45B
+1.10%+1.03%+62.53%+70.47% 67.53B
+1.28%+8.79%+16.26%+95.16% 60.74B
+0.36%+0.67%+20.48%+99.04% 55.66B
-0.96%+10.11%+21.04%+108.91% 47.97B
-1.25%+2.77%+24.06%+38.34% 45.24B
-2.41%-11.69%+175.20%+794.72% 39.08B
+1.21%+4.75%+27.30%+52.81% 35.34B
-2.22%+7.34%-39.04%+397.14% 26.49B
0.00%+1.16%+47.05%+0.06% 25.57B
Average -0.38%+2.55%+43.88%+172.06% 44B
Weighted average by Cap. -0.16%+2.78%+44.01%+156.95%

Financials

2026 *2027 *
Net sales 29.93B 4.43B 4B 3.69B 3.34B 6.31B 416B 6.5B 44.27B 17.62B 223B 16.61B 16.26B 707B 36.34B 5.38B 4.86B 4.49B 4.06B 7.66B 506B 7.89B 53.76B 21.4B 270B 20.18B 19.75B 859B
Net income 5.37B 794M 717M 662M 600M 1.13B 74.65B 1.17B 7.94B 3.16B 39.93B 2.98B 2.92B 127B 7.34B 1.09B 981M 906M 820M 1.55B 102B 1.59B 10.85B 4.32B 54.6B 4.07B 3.99B 173B
Net Debt 18.53B 2.74B 2.48B 2.29B 2.07B 3.9B 258B 4.02B 27.41B 10.91B 138B 10.29B 10.07B 438B 11.18B 1.65B 1.49B 1.38B 1.25B 2.36B 156B 2.43B 16.54B 6.59B 83.22B 6.21B 6.08B 264B
Projected Income Statement - Annual - Genmab A/S
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,244
Date Price Change Volume
12/11/26 DKK 3,530.00 -0.87% 276,750
11/11/26 DKK 3,561.00 -0.56% 201,425
10/11/26 DKK 3,581.00 -2.19% 129,461
09/11/26 DKK 3,661.00 +3.80% 141,775
06/11/26 DKK 3,527.00 -2.97% 259,891
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Genmab A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
3,530.00DKK
Average target price
4,056.77DKK
Spread / Average Target
+14.92%
  1. Stock Market
  2. Stocks
  3. GMAB Stock